Nate Pile started in the Electrical Engineering/Computer Science program at U.C. Berkeley, but wound up with a degree in Mathematics from Cal. While in school, he was lucky enough to meet and spend time working for legendary biotech analyst Jim McCamant, a life-changing experience that inspired Pile to eventually launch his own newsletter, Nate’s Notes, in 1995.
Articles by Nate Pile
The top five holdings of this ETF are: AdvisorShares Sage Core Reserves ETF (HOLD), 35.79% of assets; Fidelity Instl Govt 657 C, 4.83%; PTC Inc (PTC), 4.42%; MasTec Inc (MTZ), 3.73%; and MSCI Inc (MSCI), 3.68 %.
More than 214,000 shares have been purchased by the insiders of this biotech in the past three months. The shares are trading a very price, reflecting the company’s turnaround status.
This fund is an opportunity to diversify your biotech holdings. It has a current dividend yield of 8.87%, paid quarterly.
This healthcare fund just paid a distribution of $0.36 per share on March 31. The previous payment was in November, 2016, for $.040.
TheStreet.com also likes this biotech, recently noting, “A clear take out of the February highs, just above $117.65, could provide the spark needed to send the biotech stock sharply higher.”
From Nate’s Notes
Despite providing some very encouraging guidance at the JP Morgan Conference this...